Table II.
Course and outcomes of treatment/pregnancy.
| Oral DYD (30 mg) | MVP (600 mg) | All | |
|---|---|---|---|
| Number of subjects who underwent embryo transfer, n | 497 | 477 | 974 |
| Subjects who underwent embryo transfer after ICSI, n (%)a | 368 (74.0) | 338 (70.9) | 706 (72.5) |
| Day of embryo transfer after oocyte retrieval, n (%)a | |||
| <5 days | 350 (70.4) | 328 (68.8) | 678 (69.6) |
| ≥5 days | 147 (29.6) | 149 (31.2) | 296 (30.4) |
| Number of embryos transferred, n (%)a | |||
| 1 | 212 (42.7) | 217 (45.5) | 429 (44.1) |
| 2 | 278 (55.9) | 252 (52.8) | 530 (54.4) |
| >2 | 7 (1.4) | 8 (1.7) | 15 (1.5) |
| Number of subjects who had at least one newborn, n (%)a | 172 (34.6) | 142 (29.8) | 314 (32.2) |
| Total number of newborns, n | 213 | 158 | 371 |
| One newborn infant, n (%)b | 132 (76.7) | 126 (88.7) | 258 (82.2) |
| Two newborn infants, n (%)b | 39 (22.7) | 16 (11.3) | 55 (17.5) |
| More than two newborn infants, n (%)b | 1 (0.6) | 0 (0.0) | 1 (0.3) |
aPercentages calculated according to the number of subjects in the full analysis sample who received embryo transfer in the respective oral DYD and MVP groups.
bPercentages calculated according to the number of subjects who had at least one newborn in the respective oral DYD and MVP groups.
DYD, dydrogesterone; ICSI, intracytoplasmic sperm injection; MVP, micronized vaginal progesterone.